MIT chemical engineers have designed a
novel genetic switch that allows them to dramatically boost bacteria's
production of useful chemicals by shutting down competing metabolic pathways in
the cells.
Researchers have been trying to
engineer microbes to generate more complex products, including pharmaceuticals
and biofuels. This usually requires adding several genes encoding the enzymes
that catalyze each step of the overall synthesis.
In many cases, this approach also
requires shutting down competing pathways that already exist in the cell.
However, the timing of this shutdown is important because if the competing
pathway is necessary for cell growth, turning it off limits the population
size, and the bacteria won't produce enough of the desired compound.
A laboratory has engineered E. coli to produce glucaric acid by
adding three genes -- one each from yeast, mice, and a strain of bacteria
called Pseudomonas syringae. Using these three genes, bacteria can transform a
compound called glucose-6-phosphate into glucaric acid. However,
glucose-6-phosphate is also an intermediate in a critical metabolic pathway
that breaks down glucose and converts it into the energy cells need to grow and
reproduce.
To generate large quantities of
glucaric acid, the researchers had to come up with a way to shut down the
glucose-breakdown pathway, allowing glucose-6-phosphate to be diverted into
their alternative metabolic pathway. However, they had to carefully time the
shutdown so that the cell population would be large enough to produce a substantial
amount of glucaric acid. More importantly, they wanted to do so without adding
any new chemicals or changing the process conditions in any way.
In addition to adding the genes for
glucaric acid production, the researchers engineered each cell to produce a
protein that synthesizes a small molecule called AHL. The cells secrete this
molecule into their environment, and when the concentration surrounding the
cells gets to a certain point, it activates a switch that makes all of the
cells stop producing an enzyme called phosphofructokinase (Pfk), which is part
of the glucose breakdown pathway. With this enzyme turned off,
glucose-6-phosphate accumulates and gets diverted into the alternative pathway
that produces glucaric acid. By constructing a library of cells that produce
AHL at different rates, the researchers could identify the best time to trigger
shutdown of Pfk.
Using this switch, the researchers
were able to generate about 0.8 grams of glucaric acid per liter of the
bacterial mixture, while cells that were engineered to produce glucaric acid
but did not have the metabolic switch produced hardly any.
To demonstrate this versatility, the
researchers tested their approach with a metabolic pathway that produces a
molecule called shikimate, which is a precursor to several different amino
acids and is also an ingredient in some drugs including the influenza drug
Tamiflu. They used the AHL quorum-sensing molecule to shut off an enzyme that
moves shikimate further along in the amino acid synthesis pathway, allowing
shikimate to build up in the cells. Without the switch, the cells could not
accumulate any shikimate.
See:
Posted by Dr. Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources